Table 1.

[¹⁸F]GE180 uptake characteristics in the examined patient population

All recurrent gliomas	SUVmax (median (range))	p-value
Overall (n = 88)	1.68 (0.59–4.36)
Male (n = 56) Female (n = 32)	1.73 (0.59–3.83) 1.56 (0.59–4.36)	0.370
CNS WHO 2021 grade 2 (n = 8) CNS WHO 2021 grade 3 (n = 28) CNS WHO 2021 grade 4 (n = 52)	0.90 (0.59–3.83) 1.45 (0.59–3.82) 1.91 (0.85–3.83)	0.031
IDH-mutant (n = 46) IDH-wild type (n = 42)	1.60 (0.59–4.36) 1.89 (0.85–3.83)	0.071
IDH mut. − 1p/19 codel (n = 28) IDH mut. + 1p/19 codel (n = 18)	1.72 (.59–3.79) 1.28 (.61–4.36)	0.714
IDH wt, TERT wildtype (n = 5) IDH wt, TERT mutant (n = 22)	1.70 (1.29–3.83) 1.89 (1.00–3.12)	0.909
IDH wt, MGMT methylated (n = 19) IDH wt, MGMT unmethylated (n = 22)	2.29 (0.85–3.83) 1.81 (1.00–3.03)	0.114
Low-affinity binding status (n = 7) Medium-affinity binding status (n = 27) High-affinity binding status (n = 44)	2.32 (0.80–3.79) 1.76 (0.59–3.08) 1.58 (0.61–3.83)	0.231

SUV_max maximum standardized uptake value, CNS WHO 2021 World Health Organization Classification of Tumors of the Central Nervous System, IDH isocitrate dehydrogenase, TERT telomerase reverse transcriptase